No Mad Pursuit, Analysts Say
Ode on 'Accretion' Urn: Biogen Pays $3.25B for Tysabri Rights
By Randy Osborne
Thursday, February 7, 2013
Biogen Idec Inc.'s move to buy all rights from Elan Corp. plc to the blockbuster multiple sclerosis (MS) therapy Tysabri (natalizumab) didn't take long for analysts to applaud, though Wall Street traders spent time digesting the $3.25 billion deal, which includes contingent payments.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.